SCHEMBL4247126

SCHEMBL4247126

Fc1cccc(-c2cnc(Cl)nn2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.48
ACHE P22303 1/20 0.48
IDO1 P14902 2/20 0.47
HPGDS O60760 1/20 0.44
MAOB P27338 1/20 0.44
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
MAP4K4 O95819 2/20 0.42
KMO O15229 2/20 0.42
PIM1 P11309 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
NOTUM Q6P988 1/20 0.40
KCNQ3 O43525 1/20 0.40
KCNQ2 O43526 1/20 0.40
KCNQ5 Q9NR82 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13563179 0.80 KCNQ3 (0.49) BCHEACHEIDO1HPGDSMAP4K4
SCHEMBL28259703 0.79 KDM4E (0.50) BCHEACHEIDO1HPGDSMAOB
SCHEMBL11513041 0.79 IDO1 (0.51) IDO1MAOBKDM4EKMOGABRG2
SCHEMBL837065 0.78 MAPK1 (0.41) MAOBMEN1MAPTKMT2A
SCHEMBL837812 0.77 MEN1 (0.48) ACHEKDM4EMEN1MAPTKMT2A
SCHEMBL4251692 0.76 BCHE (0.48) BCHEACHEIDO1HPGDSMAOB
SCHEMBL11630165 0.75 MAOB (0.46) BCHEACHEIDO1HPGDSMAOB
SCHEMBL2349505 0.74 KMO (0.60) BCHEACHEIDO1HPGDSKDM4E
SCHEMBL30037423 0.71 BTK (0.51) BCHEACHEIDO1KDM4EMEN1
SCHEMBL19554588 0.71 MAOB (0.47) ACHEIDO1HPGDSMAOBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507489-B2 Bicyclic triazoles as protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
EP-2084162-B1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS INC (US) 2012-09-12 EP disclosed
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. 2009-10-15 US disclosed
CN-101553490-A Bicyclic triazoles as protein kinase modulators SGX PHARMACEUTICALS INC (US) 2009-10-07 CN disclosed
EP-2084162-A2 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-08-05 EP disclosed
WO-2008051808-A2 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS MAP3K20, TTK, PRKACB BCHE 3319/4885ACHE 4646/4885IDO1 3599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.